Table 2.
Clinical Characteristics and Outcomes During Index Hospitalization for 17 Patients Hospitalized After Receiving Sotrovimab
| Characteristic | No. (%)a |
|---|---|
| Age, y, median | 63 |
| Sex, female | 9 (52.9) |
| Unvaccinated | 2 (11.8) |
| Symptoms at hospitalization | |
| ȃFever | 13 (76.5) |
| ȃDyspnea | 9 (52.9) |
| ȃCough | 11 (64.7) |
| ȃNasal congestion | 2 (11.8) |
| ȃPoor oral intake | 7 (41.2) |
| ȃChest pain | 3 (17.6) |
| ȃFatigue | 5 (29.4) |
| CT chest findings (n = 9) | |
| ȃBilateral consolidative opacities | 2 (22.2) |
| ȃBilateral patchy ground-glass opacities | 8 (89.0) |
| CXR findings (n = 8) | |
| ȃUnilateral opacities | 3 (37.5) |
| ȃBilateral opacities | 3 (37.5) |
| ȃClear lungs | 2 (25) |
| Oxygen requirement | |
| ȃNo oxygen requirement or <24 h | 11 (64.7) |
| ȃNasal cannula (>24 h) | 4 (23.5) |
| ȃHigh-flow oxygen | 1 (5.9) |
| ȃMechanical ventilation | 1 (5.9) |
| COVID-19 severityb | |
| ȃMild | 11 (64.7) |
| ȃModerate | 4 (23.5) |
| ȃSevere/critical | 2 (11.8) |
| COVID-19 treatment | |
| ȃAny COVID-19 treatment | 14 (82.4) |
| ȃRemdesivir | 13 (76.5) |
| ȃDexamethasone | 6 (35.3) |
| ICU-level care for COVID-19 | 1 (5.9) |
| Outcomes | |
| ȃCOVID-19–related deathc | 3 (17.6) |
| ȃCOVID-19–related readmission | 4 (23.5) |
| ȃChronic infectiond | 3 (17.6) |
| Length of stay, d, median (range) | 8 (1–64) |
Abbreviations: COVID-19, coronavirus disease 2019; CT, computed tomography; CXR, chest radiograph; ICU, intensive care unit.
Patients can be in >1 category.
COVID-19 severity based on maximum oxygen requirement through admission. Mild infections remained on room air or required nasal cannula <24 hours; moderate infections required nasal cannula >24 hours; severe/critical infections required high-flow oxygen or intubation.
COVID-19–related deaths are based on review of electronic medical records and clinical judgment of patient presentation/illness in relation to the patients’ primary disease and time from COVID-19 positivity.
Chronic COVID-19 infection is defined as patients who have had progressive or recurrent COVID-19–related symptoms (or require home oxygen) with imaging consistent with COVID-19 and, in the absence of an alternate etiology, with or without evidence of viral persistence.